Photo by Vitaly Gariev on Unsplash
Health Insurers to Cover Off-Label Long Covid Drugs
In a recent move that significantly affects Long Covid patients in Germany, statutory health insurers will now cover the cost of four specific medications prescribed for Long Covid symptoms. Previously, patients often had to pay for these treatments out of pocket, despite their potential to alleviate persistent symptoms like fatigue and cognitive impairment. This decision comes after the Gemeinsame Bundesausschuss (G-BA), Germany’s Federal Joint Committee responsible for healthcare reimbursement decisions, approved these drugs for Off-label use in Long Covid therapy.
The four drugs covered include Agomelatin, an antidepressant used to treat Fatigue, and Ivabradin, which is used for post-infectious Postural Orthostatic Tachycardia Syndrome (PoTS). Additionally, Metformin, commonly prescribed for diabetes, is noted for its potential to prevent Long Covid in certain overweight patients. Another drug, Vortioxetin, is used against cognitive problems associated with Long Covid. Although these medications lack formal approval specifically for Long Covid, the G-BA’s resolution allows for reimbursement when prescribed by doctors [Source 1][Source 2][Source 5][Source 8].
Context and Implementation of New Coverage
The approval of these Off-label treatments follows an expert evaluation initiated by the Federal Institute for Drugs and Medical Devices (BfArM) and the Ministry of Health. The expert group assessed these four substances for medical benefit in managing Long and Post Covid syndromes. The G-BA’s decision, which will require confirmation by the Federal Ministry of Health, represents an expedited response to the urgent need for treatment options, given that no medications are officially licensed specifically for Long Covid so far [Source 5][Source 8].
According to Charité Berlin’s Dr. Carmen Scheibenbogen, this decision sends an important signal and offers hope for improved patient care. Estimates suggest around one million people in Germany suffer from Long Covid symptoms, which include severe fatigue and cognitive impairments, making this coverage expansion highly relevant [Source 3][Source 7].
Practical Implications for Expats and Foreign Workers
This development is particularly pertinent for expats, international students, and foreign workers living in Germany who are insured under the statutory health system (gesetzliche Krankenversicherung). Before this change, Long Covid patients often faced substantial out-of-pocket expenses for these therapies. Now, prescribed Off-label use of these four medications will be reimbursed, reducing financial barriers to treatment.
Expats experiencing long-lasting symptoms after a COVID-19 infection should consult their doctors about these newly reimbursable options. It is important to note that these drugs remain Off-label treatments, which means their prescription is based on medical discretion rather than formal approval for Long Covid. Patients should verify that their health insurance covers these prescriptions under the new G-BA regulations once approved by the Ministry of Health. This action could significantly improve access to therapies addressing common Long Covid complaints such as Fatigue, cognitive deficits, and PoTS [Source 1][Source 3].
For more detailed information and continual updates, patients and healthcare providers can refer to the official press releases and trusted health news websites.
Original article: Tagesschau on Long Covid medication reimbursement [Source 1]
